Evropská unie - čeština - EMA (European Medicines Agency)

vericel denmark aps - autologní kultivované chondrocyty - zlomeniny, chrupavka - jiné léky na poruchy muskuloskeletálního systému - oprava symptomatických poruch chrupavky kolena.

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

opella healthcare czech s.r.o., praha array - 1593 ibuprofen - měkká tobolka - 400mg - ibuprofen

Evropská unie - čeština - EMA (European Medicines Agency)

merck sharp & dohme b.v. - virus varicella-zoster (živý, atenuovaný) - herpes zoster; immunization - vírové vakcíny - zostavax je indikován k prevenci herpes zoster ("zoster" nebo šindelů) a postherpetické neuralgie související s herpes zoster. zostavax je indikován k imunizaci jedinců ve věku 50 let nebo starší.

Evropská unie - čeština - EMA (European Medicines Agency)

glaxosmithkline biologicals sa - recombinant varicella zoster virus glycoprotein e - herpes zoster - vakcíny - shingrix is indicated for prevention of herpes zoster (hz) and post-herpetic neuralgia (phn), in:adults 50 years of age or older;adults 18 years of age or older at increased risk of hz. použití shingrix by měla být v souladu s oficiálními doporučeními.

Evropská unie - čeština - EMA (European Medicines Agency)

biogen netherlands b.v. - dimethyl fumarát - roztroušená skleróza - imunosupresiva - tecfidera is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Evropská unie - čeština - EMA (European Medicines Agency)

biogen netherlands b.v. - natalizumab - roztroušená skleróza - selektivní imunosupresiva - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 a 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Evropská unie - čeština - EMA (European Medicines Agency)

mylan ireland limited - fingolimod hydrochlorid - roztroušená skleróza, relaps-remitentní - imunosupresiva - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 a 5. 1)orpatients s rychle se vyvíjející těžkou relabující-remitentní formou roztroušené sklerózy definovanou 2 nebo více relapsy v jednom roce a s 1 nebo více gadolinium enhancing lézí na mri mozku nebo významné zvýšení zátěže t2 lézí ve srovnání s předchozí nedávnou mri.

Evropská unie - čeština - EMA (European Medicines Agency)

mylan ireland limited - fingolimod hydrochlorid - roztroušená skleróza, relaps-remitentní - imunosupresiva - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 a 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Evropská unie - čeština - EMA (European Medicines Agency)

biogen netherlands b.v. - diroximel fumarate (biib098) - roztroušená skleróza, relaps-remitentní - imunosupresiva - vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5. 1 for important information on the populations for which efficacy has been established).

Evropská unie - čeština - EMA (European Medicines Agency)

janssen-cilag international n.v.    - ponesimod - roztroušená skleróza, relaps-remitentní - imunosupresiva - ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.